Sunesis Pharmaceuticals (SNSS) is currently trading around 71 cents a share with rumors of a possible buyout from Abbvie (ABBV).
Analysts has a price target of $4 per share as confirmed. Reasons why this stock is a great hold until a possible buyout is because Sunesis now has a connection to Abbvie with Deepali Suri the VP of Clinical Operations.
Suri has formerly worked for Pharmacyclics (an Abbvie company) with both Pharmacylics and Sunesis targeting oncology and cancer therapies.
Sunesis is a Great Acquisition for Abbvie
With both companies going after cancer, Sunesis stands as a great acquisition for Abbvie. Abbvie is in the business of pharmaceutical research and development of therapies. There is no reason why they wouldn’t buy Sunesis.
Another reason why Sunesis is a great fit is because of combination therapies, the company has a great pipeline but studies show that their candidates also work in combination to other therapies.
The reason why they can combine their candidate with other therapies for a greater outcome is because of their main candidate, Vecabrutinib (SNS-062) which is a BTK inhibitor that targets b-cell malignancies.
